Attached files
| file | filename |
|---|---|
| EX-31.1 - MyMD Pharmaceuticals, Inc. | ex31-1.htm |
| 10-Q - MyMD Pharmaceuticals, Inc. | form10-q.htm |
| EX-31.2 - MyMD Pharmaceuticals, Inc. | ex31-2.htm |
| EX-3.3 - MyMD Pharmaceuticals, Inc. | ex3-3.htm |
| EX-3.2 - MyMD Pharmaceuticals, Inc. | ex3-2.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report of Akers Biosciences, Inc. (the “Company”), on Form 10-Q for the period ended June 30, 2020, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. |
| Date: August 14, 2020 | By: | /s/ Christopher C. Schreiber |
| Christopher C. Schreiber | ||
Executive Chairman of the Board of Directors and Director (Principal Executive Officer) | ||
| Akers Biosciences, Inc. |
| Date: August 14, 2020 | By: | /s/ Howard Yeaton |
| Howard Yeaton | ||
Interim Chief Financial Officer (Principal Financial and Accounting Officer) | ||
| Akers Biosciences, Inc. |